Under a tenth of individuals that would benefit from weight-loss injections like Wegovy have access to them, states the WHO as it releases its initial advice on the therapies.
Given in excess of 1,000,000,000 people worldwide now obese, it is urging broader and more equitable availability to this class of drugs.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a lifelong illness that can be managed with holistic and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key barriers to widespread access to the treatments that can aid individuals in losing considerable body mass, notes the agency.
Skinny Jab Scarcity
Even in the current most favorable case, the manufacturing of these medications would only suffice for about 100 million people – fewer than 10% of the global need, according to the health organization.
The guideline calls on countries and companies to increase access, via strategies such as licensing agreements.
Exclusive production rights on a key compound – the core component of the drug Wegovy – is set to lapse in multiple countries in 2026.
How Weight-Loss Drugs Operate
The injections replicate a natural hormone to delay gastric emptying, reduce hunger and increase satiety so individuals reduce food intake.
Patients typically see weight reduction in the initial weeks of beginning the weekly injections.
Research indicates patients may put most of the weight back on a year later of halting the drug, when their typical hunger resume.
Being carrying excess weight elevates your chance for experiencing health problems, such as diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight impacts people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.
